A prediction model based on PET/CT images and clinicopathological characteristics provided a novel strategy for clinicians to screen the NSCLC patients who could benefit from the anti-PD-L1 immunotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.